Brief: Blueprint Medicines Provides 2023 Portfolio Goals
05/01/2023 14:14
Jan 5 (Reuters) - Blueprint Medicines Corp BPMC.O :
* PROVIDES 2023 PORTFOLIO GOALS TO ACHIEVE PRECISION AT
SCALE
* BLUEPRINT MEDICINES-EXPECT TO ACHIEVE HIGH-END OF 2022
TOTAL
REVENUE GUIDANCE OF $180 MILLION-$200 MILLION,AYVAKIT PRODUCT
REVENUE GUIDANCE OF $108 MILLION-$111 MILLION
* BLUEPRINT MEDICINES-POSITIONED FOR SIGNIFICANT NEAR-TERM
GROWTH
WITH POTENTIAL FDA APPROVAL OF AYVAKIT IN INDOLENT SYSTEMIC
MASTOCYTOSIS IN MIDDLE 2023
Source text for Eikon: ID:nPn75p5Mba
Further company coverage: BPMC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Blueprint Medicines
See all newsBrief: Sanofi Announces Extension Of Blueprint Tender Offer
Brief: Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit
U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle
UBS raises Blueprint Medicines' PT on Sanofi's up to $9.5 billion takeover deal
U.S. RESEARCH ROUNDUP-Biomea Fusion, GE Aerospace, P&G